Latest filings (excl ownership)
15-12G
Securities registration termination
6 Oct 23
8-K
Termination of a Material Definitive Agreement
26 Sep 23
POSASR
Automatic shelf registration (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
25-NSE
Exchange delisting
26 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
21 Sep 23
DEFA14A
Additional proxy soliciting materials
12 Sep 23
8-K
Other Events
12 Sep 23
DEFM14A
Proxy related to merger
22 Aug 23
PREM14A
Preliminary proxy related to merger
11 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
DEFA14A
Additional proxy soliciting materials
31 Jul 23
8-K
Voting and Support Agreement
31 Jul 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
8-K
Biogen to Acquire Reata Pharmaceuticals
28 Jul 23
8-K
Entry into a Material Definitive Agreement
10 Jul 23
8-K
Entry into a Material Definitive Agreement
20 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
S-8
Registration of securities for employees
2 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
1 Mar 23
8-K
Reata Pharmaceuticals SKYCLARYS™ (Omaveloxolone) Approval Conference Call Script
28 Feb 23
10-K
2022 FY
Annual report
24 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
REATA PHARMACEUTICALS, INC. ANNOUNCES third QUARTER 2022 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS
8 Nov 22
Latest ownership filings
SC 13D/A
BIOGEN INC.
28 Sep 23
4
Antal Rohit Desai
28 Sep 23
SC 13D/A
CPMG Inc
28 Sep 23
4
R Kent McGaughy Jr
26 Sep 23
SC 13D/A
ROSE WILLIAM
26 Sep 23
4
MICHAEL D WORTLEY
26 Sep 23
4
Christy J. Oliger
26 Sep 23
4
Andrea Loewen
26 Sep 23
4
Manmeet Singh Soni
26 Sep 23
4
WILLIAM ROSE
26 Sep 23
4
Shamim Ruff
26 Sep 23
4
Colin John Meyer
26 Sep 23
4
Dawn Carter Bir
26 Sep 23
4
Rajiv Patni
26 Sep 23
4
Steven Ryder
26 Sep 23
4
James Warren Huff
26 Sep 23
4
Martin Edwards
26 Sep 23
4
William D. Jr. McClellan
26 Sep 23
4
Bhaskar Anand
26 Sep 23
SC 13D/A
ROSE WILLIAM
19 Sep 23
4
WILLIAM ROSE
19 Sep 23
4
Andrea Loewen
18 Sep 23
144
Notice of proposed sale of securities
14 Sep 23
4
Bhaskar Anand
7 Sep 23
144
Notice of proposed sale of securities
5 Sep 23
144
Notice of proposed sale of securities
5 Sep 23
4
WILLIAM ROSE
24 Aug 23
SC 13D/A
ROSE WILLIAM
24 Aug 23
4
MICHAEL D WORTLEY
17 Aug 23
4
Manmeet Singh Soni
17 Aug 23
4
Colin John Meyer
17 Aug 23
4
Dawn Carter Bir
17 Aug 23
4
Bhaskar Anand
17 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
144
Notice of proposed sale of securities
15 Aug 23